Catalent

Catalent is a leading global CDMO with a mission to develop, manufacture, and supply products that help people live better and healthier lives. The company has established itself as a pivotal partner in the biopharma supply chain, delivering over 1,000 therapies and producing 60+ billion doses annually through its integrated service platforms in oral dose, biologics, specialty drug delivery, and clinical supply. Its strategy is built on a 'Patient First' mindset, strategic acquisitions to expand capabilities, and leveraging proprietary technologies to de-risk and accelerate clients' paths to market.

A diversified suite of proprietary drug delivery and manufacturing technologies, including leading oral platforms (Softgel, Zydis®), biologics platforms (GPEx®), and advanced modality capabilities for cell and gene therapy.

Catalent competes with large, diversified CDMOs like Lonza and Thermo Fisher, as well as specialized firms in oral dose, biologics, and advanced therapies. Its advantages include leading oral tech (Softgel, Zydis®), an end-to-end service model, and a strong foothold in cell and gene therapy manufacturing.